Pyxis Oncology (PYXS) Competitors $3.82 -0.34 (-8.17%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PYXS vs. MGNX, ADCT, RANI, ACET, STTK, BCYC, PAHC, COLL, IMTX, and AVBPShould you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include MacroGenics (MGNX), ADC Therapeutics (ADCT), Rani Therapeutics (RANI), Adicet Bio (ACET), Shattuck Labs (STTK), Bicycle Therapeutics (BCYC), Phibro Animal Health (PAHC), Collegium Pharmaceutical (COLL), Immatics (IMTX), and ArriVent BioPharma (AVBP). These companies are all part of the "medical" sector. Pyxis Oncology vs. MacroGenics ADC Therapeutics Rani Therapeutics Adicet Bio Shattuck Labs Bicycle Therapeutics Phibro Animal Health Collegium Pharmaceutical Immatics ArriVent BioPharma Pyxis Oncology (NASDAQ:PYXS) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends. Does the media favor PYXS or MGNX? In the previous week, Pyxis Oncology had 16 more articles in the media than MacroGenics. MarketBeat recorded 18 mentions for Pyxis Oncology and 2 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.97 beat Pyxis Oncology's score of 0.00 indicating that MacroGenics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate PYXS or MGNX? Pyxis Oncology currently has a consensus target price of $9.57, indicating a potential upside of 150.56%. MacroGenics has a consensus target price of $7.63, indicating a potential upside of 132.47%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Pyxis Oncology is more favorable than MacroGenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00MacroGenics 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36 Which has higher earnings and valuation, PYXS or MGNX? MacroGenics has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPyxis Oncology$16.15M14.07-$73.79M-$1.03-3.71MacroGenics$139.77M1.47-$9.06M-$1.58-2.08 Does the MarketBeat Community favor PYXS or MGNX? MacroGenics received 402 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 82.76% of users gave Pyxis Oncology an outperform vote while only 62.28% of users gave MacroGenics an outperform vote. CompanyUnderperformOutperformPyxis OncologyOutperform Votes2482.76% Underperform Votes517.24%MacroGenicsOutperform Votes42662.28% Underperform Votes25837.72% Which has more risk & volatility, PYXS or MGNX? Pyxis Oncology has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Do insiders and institutionals have more ownership in PYXS or MGNX? 39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 9.8% of Pyxis Oncology shares are held by insiders. Comparatively, 11.3% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is PYXS or MGNX more profitable? Pyxis Oncology has a net margin of 0.00% compared to MacroGenics' net margin of -69.07%. Pyxis Oncology's return on equity of -36.22% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets Pyxis OncologyN/A -36.22% -28.76% MacroGenics -69.07%-89.42%-38.57% SummaryPyxis Oncology beats MacroGenics on 10 of the 19 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYXS vs. The Competition Export to ExcelMetricPyxis OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$227.16M$6.45B$5.04B$8.81BDividend YieldN/A8.11%5.16%4.07%P/E Ratio-3.7110.78130.5317.82Price / Sales14.07243.701,183.8674.55Price / CashN/A22.1633.6132.53Price / Book1.365.474.684.68Net Income-$73.79M$153.61M$119.23M$226.08M7 Day Performance-10.75%-2.00%-1.83%-1.04%1 Month Performance3.80%-7.46%-3.61%1.04%1 Year Performance167.13%31.82%31.74%26.28% Pyxis Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYXSPyxis Oncology1.0428 of 5 stars$3.82-8.2%$9.57+150.6%+165.3%$247.38MN/A-3.7160News CoverageGap UpHigh Trading VolumeMGNXMacroGenics3.8684 of 5 stars$3.28-5.7%$7.63+132.5%-57.0%$218.42M$58.75M0.00430ADCTADC Therapeutics2.8805 of 5 stars$1.98-3.9%$8.25+317.7%+177.9%$190.96M$70.72M-0.83310Positive NewsRANIRani Therapeutics3.1555 of 5 stars$2.05-0.5%$11.71+471.4%+2.5%$109.75M$2.72M0.00110Analyst ForecastACETAdicet Bio2.5176 of 5 stars$0.97-5.8%$7.50+675.5%-17.3%$84.87M$24.99M0.0090Analyst ForecastHigh Trading VolumeSTTKShattuck Labs2.8175 of 5 stars$1.11-2.6%$8.67+680.8%-50.7%$54.42M$1.66M0.00100Analyst RevisionBCYCBicycle Therapeutics2.8475 of 5 stars$20.36-0.6%$40.13+97.1%+49.4%$968.12M$26.98M-6.19240Analyst RevisionPAHCPhibro Animal Health4.2227 of 5 stars$23.39-1.5%$16.50-29.5%+123.4%$961.95M$1.02B54.401,940Analyst DowngradeCOLLCollegium Pharmaceutical3.9744 of 5 stars$30.00+0.8%$42.60+42.0%+17.2%$959.45M$566.77M12.93210IMTXImmatics2.0118 of 5 stars$7.80-0.1%$16.67+113.7%-9.2%$930.98M$70.87M-8.76260Analyst ForecastNews CoverageAVBPArriVent BioPharma1.0036 of 5 stars$27.410.0%$36.80+34.3%N/A$923.64MN/A0.0040 Related Companies and Tools Related Companies MGNX Alternatives ADCT Alternatives RANI Alternatives ACET Alternatives STTK Alternatives BCYC Alternatives PAHC Alternatives COLL Alternatives IMTX Alternatives AVBP Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PYXS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide vic...Wide Moat Research | SponsoredThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of ...WealthPress | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
